Floatz logo

Aguix

Stereotactic Radiation

Brigham and Women's HospitalPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Stereotactic Radiation cohort.

Asset / SponsorPhaseRating
Osimertinib
Fudan University
D

Same molecule, other indications

Aguix is also rated in:

digestive system cancerDormant
CCC
Indicative ·
53 / 100
View asset →
brain cancerDormant
CCC
Indicative ·
53 / 100
View asset →
central nervous system cystDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →